Serum pancreastatin: The Long Sought Universal, sensitive, specific tumor marker for neuroendocrine tumors?

Pancreas

Volumn 41, Issue 4, 2012, Pages 505-507

  Ito, Tetsuhide ^a   Igarashi, Hisato ^a   Jensen, Robert T ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINO ACID; CHROMOGRANIN; GASTRIN; PANCREASTATIN; SEROTONIN; TUMOR MARKER;

BIOLOGICAL ACTIVITY; CARCINOID SYNDROME; EARLY DIAGNOSIS; ENDOSCOPY; GLYCOSYLATION; HUMAN; MOLECULAR WEIGHT; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; TUMOR VOLUME;

CHROMOGRANIN A; FEMALE; GASTRINS; HUMANS; MALE; PANCREAS; PANCREATIC HORMONES; PROTON PUMP INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859929476     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318249a92a     Document Type: Review

References (21)

1. Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-1289.
2. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008;9:61-72.
3. Scherubl H, Jensen RT, Cadiot G, et al. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc. 2011;3:133-139.
4. Raines D, Chester M, Diebold A, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012 March 28. [Epub ahead of print].
5. Goebel SU, Serrano J, Yu F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85:1470-1483. (Pubitemid 29152818)
6. Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A: Biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010;17:2427-2443.
7. Helle KB, Corti A, Metz-Boutigue MH, et al. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci. 2007;64:2863-2886. (Pubitemid 351152248)
8. Portela-Gomes GM, Grimelius L, Wilander E, et al. Granins and granin-related peptides in neuroendocrine tumors. Regul Pept. 2010;165:12-20.
9. Konecki DS, Benedum UM, Gerdes HH, et al. The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 1987;262:17026-17030. (Pubitemid 18017665)
10. Tartaglia A, Portela-Gomes GM, Oberg K, et al. Chromogranin A in gastric neuroendocrine tumors: an immunohistochemical and biochemical study with region-specific antibodies. Virchows Arch. 2006;448:399-406.
11. Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology. 2011;140:1444-1453.
12. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010;39:611-616.
13. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin as a marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6:820-827.
14. Jensen RT. Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4-19.
15. Pregun I, Herszenyi L, Juhasz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion. 2011;84:22-28.
16. Udupi V, Lee HM, Kurosky A, et al. Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin. Regul Pept. 1999;83:123-127. (Pubitemid 29393031)
17. Schmidt WE, Siegel EG, Kratzin H, et al. Isolation and primary structure of tumor-derived peptides related to human pancreastatin and chromogranin A. Proc Natl Acad Sci USA. 1988;85:8231-8235.
18. Kimura W, Jimi A, Miyasaka K, et al. Immunohistochemical study of the distribution of pancreastatin in endocrine tumors of the pancreas and in normal pancreatic tissue: analysis of autopsy cases. Pancreas. 1991;6:688-693.
19. Kitayama N, Tateishi K, Funakoshi A, et al. Pancreastatin molecular forms in normal human plasma. Life Sci. 1994;54:1571-1578. (Pubitemid 24180096)
20. Syversen U, Mignon M, Bonfils S, et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol. 1993;32:161-165. (Pubitemid 23188530)
21. Stronge RL, Turner GB, Johnston BT, et al. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumors. Ann Clin Biochem. 2008;45:560-566.